Company: Novalar Pharmaceuticals
Based: San Diego, CA
Investors: Domain Associates, Montreux Equity Partners, New Enterprise Associates, S.R. One, Undisclosed Venture Firm
Scoop: Novalar is focused on developing oral healthcare therapies. It's lead product--NV-101--is designed to reverse the lingering and debilitating lip and tongue numbness associated with local dental anesthesia. It was submitted to the FDA in June of 2007. The funding will help Novalar commercialize NV-101 if approved by the FDA.